甲基丁衍生物在治疗鼻节功能障碍:一个系统的审查
Hunter R Roth1, Justin P Reinert
1From the Department of Pharmacy Practice, The University of Toledo College of Pharmacy and Pharmaceutical Sciences, Toledo, OH.
Cardiology in review
|November 1, 2023
概括
甲基丁,如神ophylline和aminophylline有效地增加心率,并减少bradyarrhythmias在鼻节功能障碍. 它们看起来是安全的,可以作为节拍的桥梁,尽管最佳剂量需要进一步研究.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 虽然已知theophylline和aminophylline的时长效应,但它们在节功能障碍中的使用缺乏全面的审查.
- 节功能障碍可能导致肌不整,影响心率和患者的幸福感.
研究的目的:
- 系统地审查甲基丁的疗效和安全性,用于治疗节功能障碍中的节律失常症.
- 评估甲基丁作为这些疾病的潜在药理疗法.
主要方法:
- 按照PRISMA指南进行了系统审查.
- 搜索了Embase,PubMed,MEDLINE,Cochrane Central,科学网,SciELO,KCI,全球医学指数和CINAHL,截至2023年6月.
- 包括从最初的607个确定的14项研究.
主要成果:
- 甲基丁 (神ophylline,aminophylline) 增加了心率,并减少了胸节律的复发.
- 症状解决数据是相互矛盾的;一些病例研究显示改善,而一个RCT没有发现显著差异.
- 在所有研究设计中,不良影响是罕见的.
结论:
- 甲基丁表明安全性和有效性,用于bradyarrhythmic表现的鼻节功能障碍.
- 它们可以作为替代或桥梁疗法,以非药物节奏.
- 需要进一步的研究,以确定各种适应症的最佳剂量.
相关概念视频
Antiasthma Drugs: Methylxanthines
242
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
242
Dysrhythmias VI: Management of Dysrhythmias
16
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
16
Heart Failure Drugs: Inotropic Agents
598
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
598
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
751
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
751
Adrenergic Agonists: Mixed-Action Agents
752
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
752
Heart Failure V: Medical Management
9
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
9


